Despite what free market fanatics believe... the free market is a
two-edged sword. Competition CAN help to lower prices as manufactures
find new ways to streamline the production process of standardized
items... but it's just as likely companies will seek to create private
monopolies within a competitive market to trap consumers in a
proprietary system to keep prices (and thus profits) high.
Case in point: the pharmaceutical industries. Because of their special
position they know that people will be willing to spend ANYTHING to
cure a disease, live a productive life, end pain, or save a life of
themselves or a love one. In classic free market style... the industry
has made a business of sucking up every available dollar it can.
The sad part is the industry that holds the promise of the above
abounds in waste NOT efficiency. Companies waste development resources
by constantly trying to reinvent each other's wheel. If one company
comes up with a profitable proton inhibiter to reduce stomach acid...
they all have to get in on the action. Such competition is supposed to
drive the price of drugs down. We typically don't see drastic drops in
prices until a drug goes generic and companies THEN are actually free
to compete to LOWER the prices. I recently bought generic Claritin at
a wholesale club for a dime a tab which must be closer to the true price of production. According to :
http://216.239.41.104/search?q=cache:aX6hwLlsgeAJ:http://www.cojoweb.com/ref-online%2520prescriptions.htmlName brand Claritin was $63 for 30 pills in the US... about 200X as
expensive as what I paid.
Companies piss away BILLIONS in direct to consumer (DTC) advertising
to lure patients into pestering their doctor for their drugs. The
strategy is not just to keep demand up so high prices can be
maintained... but that consumers will pay for those added costs of the
ads. Imagine that: paying to not only be propagandized but to be
ripped off!
In 1998... a year where I could get credible figures for the spending
habits of the pharmaceutical industry they spent $24.4 BILLION on
R&D.... and $12.7 BILLION on marketing. Sources below.
But getting back to reinventing each other's wheel. According to
Public Citizen.... "Drug industry R&D is made less risky by the fact
that only about 22 percent of the new drugs brought to market in the
last two decades were innovative drugs that represented important
therapeutic gains over existing drugs. Most were "me-too" drugs, which
often replicate existing successful drugs." Source:
http://www.citizen.org/congress/campaign/special_interest/articles.cfm?ID=6538We saw this strategy when Prilosec was coming off patent. Rather than put resources into developing drugs to treat new diseases... AstraZenaca poured resources into protecting a cash cow. Expensive clinical trials were rigged to compare higher doses of Nexium against Prilosec to find some way to justify the new drug. A huge $500 million dollar advertising campaign was launched to get consumers to switch to Nexium... a drug with few if any new therapeutic benefits. Here's a copy of damning article from the Wall Street Journal
http://home.cwru.edu/activism/READ/WSJ060602.htmlNow there's no good way to determine whether the development of those
truly innovative drugs is directly proportional to their R&D budget so
let's say "only" 50% of this R&D budget is wasted on copy-cat drugs...
not 78%. What we start off with is $37.1 Billion pool of money in 1998... of which some $24.6 Billion is pissed away NOT developing new innovative drugs.... $24.6 Billion pissed away on the competitive overhead... the games corporations play. And this is supposed to represent how free markets are always efficient... bringing to market the best product at the best price? This is an example of a dysfunctional free market run amok! And to keep to prevent reform... they now spend another 262 MILLION a year trying to manipulate the federal government.
http://www.citizen.org/congress/campaign/special_interest/articles.cfm?ID=6538 This investment obviously paid off in the Medicare Drug law that protected the high profits of drug companies.
In the early days of the Republic corporations were rightfully
distrusted and only chartered to do a public good. If they failed in their goals... the company lost its charter.
It's about time we looked again how corporations are chartered... and in some special cases the charters of corporations like the drug industry should be restricted and made goal oriented as the electrical utilities once were.
We are at war with disease and death. In this war when a person can
not afford the medication they need or a drug is held up because of
wasteful use of resources, we ALL lose. The drug companies had their
chance to be socially responsible corporate citizens and they blew it. We simply can NOT literally afford to let the drug companies do business as usual.
SOURCES
http://www.aegis.com/news/wb/1999/WB990801.htmlCiting the annual reports of the 15 largest pharmaceutical companies,
AIDS Action said the companies spent a collective $68.4 billion on
marketing and administration in 1998 and while they spent only $24.4
billion on research and development. They reaped a collective $224.2
billion in gross sales. The report also stresses that many AIDS drugs
are developed in part with federal funding.
http://mednews.stanford.edu/news_releases_html/2003/mayrelease/Pharmaceutical.htmThe study is based on 1998 data from IMS Health, an independent
pharmaceutical market-research company, on promotion expenditures for
the 250 most promoted medications in the United States. Researchers
analyzed the data to determine the amount of money spent marketing
these products and the principal strategies used to promote them.
The resulting estimate of $12.7 billion is high not only in absolute
terms but in relative terms, Ma noted, as the pharmaceutical industry
ranks 34th among the 200 U.S. industries with the largest advertising
expenditures.
The study also found that drug promotion efforts were concentrated on
a relatively small number of medications. Promotion of the top 50
drugs, for example, accounted for 51.6 percent of total drug-promotion
spending in 1998.
The study found that the most dominant drug-promotion strategies in
1998 were traditional, time-tested methods. Free samples given to
physicians totaled $6.6 billion of retail value, representing 51.9
percent of the drug promotion expenditures. Pitches by drug-industry
reps to in-office physicians - a practice known as detailing - totaled
$3.5 billion, accounting for 27.8 percent of the total. Ads in medical
journals totaled $540 million, representing a modest 4.3 percent of
total drug-promotion expenditures.
(Note: I posted this to Usenet a few months ago. I hope the links are still vaild.)